TRANSFAC FACTOR TABLE, Release 2017.2 - public - 2017-06-30, (C) QIAGEN

AC T02368 XX ID T02368 XX DT 25.03.1998 (created); ili. DT 08.06.2015 (updated); asv. CO Copyright (C), QIAGEN. XX FA HMGIY XX SY high mobility group AT-hook 1; High mobility group AT-hook protein 1; High mobility group protein A1; High mobility group protein HMG-I/HMG-Y; High mobility group protein-R; HMG-I(Y); HMG-R; HMGA1; HMGA1c; HMGIY; MGC12816; MGC4242; MGC4854; nonhistone chromosomal high-mobility group protein HMG-I/HMG-Y. XX OS human, Homo sapiens OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; primates XX GE G004779 HMGA1; HGNC: HMGA1. XX CL C0083; AT-hook; XX SF 2 splice variants HMGIY T01851 and HMG Y T01980; XX CP increased expression in various types of cancer [4]; DLD-1, HCT116, SW480, HT29 [12]. CN Colo-205, Caco-2 [12]. XX FF architectural factor that specifically recognizes the minor groove of AT-rich portions of DNA [1]; FF transcription factor, look up the TRANSFAC cross reference for more details; FF binds to S/MAR DNA [2]; FF recognizes specifically base-unpairing regions [4]; FF mediates redistribution of histone H1 [2]; FF supposed to interact with major groove binding trans-activators through its acidic C-terminal domain [1]; FF interacts directly with JunB and Fra-2 [7]; FF essential component of IFN-beta enhanceosome [5]; FF essential component of HPV18 enhanceosome [6] [7]; FF induced by TPA in K562 erythroleukemia cells [3]; FF mRNA and protein expression is activated by endotoxin and IL-1beta in vascular smooth muscle cells [9]; FF activates (cooperatively with AP-1 factors) CD44 gene in response to IL-1beta [8]; XX IN T08146 AP-2alpha; human, Homo sapiens. IN T33762 DRIP205; human, Homo sapiens. IN T08100 EWS; human, Homo sapiens. IN T01991 Fra-2; human, Homo sapiens. IN T01977 JunB; human, Homo sapiens. IN T10037 PU.1; Mammalia. IN T33112 TRF2; human, Homo sapiens. XX MX M01653 V$HMGIY_01. MX M01010 V$HMGIY_Q3. MX M07320 V$HMGIY_Q3_01. MX M01879 V$HMGIY_Q4. MX M00750 V$HMGIY_Q6. XX BS R30222. BS R30223. BS R30224. BS R30225. BS R30226. BS R30227. BS R30228. BS R30229. BS R30230. BS R30231. BS R30232. BS R30233. BS R30234. BS R30235. BS R30236. BS R30237. BS R30238. BS R30239. BS R30240. BS R30241. BS R30242. BS R30243. BS R30244. BS R30245. BS R30246. BS R30247. BS R30248. BS R30249. BS R30250. BS R30251. BS R30252. BS R30253. BS R30254. BS R30255. BS R30256. BS R30257. BS R30258. BS R14456. BS R14461. BS R14462. BS R14463. BS R14464. BS R14465. BS R14466. BS R68150. BS R68148. BS R67986. BS R35330. BS R04931. BS R59454. BS R14727. BS R14728. BS R14731. BS R14732. BS R37313. BS R14809. BS R14810. BS R14811. BS R35341. BS R16980. BS R16981. BS R24860. BS R20851. BS R68152. BS R38974. BS R34669. BS R68153. BS R14765. BS R05081. BS R34652. BS R37387. BS R34662. XX DR TRANSPATH: MO000026358. DR SMARTDB: SB000028. DR UniProtKB: P17096; XX RN [1]; RE0006730. RX PUBMED: 7479086. RA Wood L. D., Farmer A. A., Richmond A. RT HMGI(Y) and Sp1 in addition to NF-kappaB regulate transcription of the MGSA/GROalpha gene RL Nucleic Acids Res. 23:4210-4219 (1995). RN [2]; RE0007113. RX PUBMED: 8344261. RA Zhao K., Kaes E., Gonzalez E., Laemmli U. K. RT SAR-dependent mobilization of histone H1 by HMG-I/Y in vitro: HMG-I/Y is enriched in H1-depleted chromatin RL EMBO J. 12:3237-3247 (1993). RN [3]; RE0011923. RX PUBMED: 7775485. RA Ogram S. A., Reeves R. RT Differential regulation of a multipromoter gene RL J. Biol. Chem. 270:14235-14242 (1995). RN [4]; RE0014852. RX PUBMED: 10582687. RA Liu W.-M., Guerra-Vladusic F. K., Kurakata S., Lupu R., Kohwi-Shigematsu T. RT HMG-I(Y) recognizes base-unpairing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype RL Cancer Res. 59:5695-5703 (1999). RN [5]; RE0016568. RX PUBMED: 8374955. RA Du W., Thanos D., Maniatis T. RT Mechanism of transcriptional synergism between distinct virus-inducible enhancer elements. RL Cell 74:887-898 (1993). RN [6]; RE0023641. RX PUBMED: 12640118. RA Bouallaga I., Teissier S., Yaniv M., Thierry F. RT HMG-I(Y) and the CBP/p300 coactivator are essential for human papillomavirus type 18 enhanceosome transcriptional activity. RL Mol. Cell. Biol. 23:2329-2340 (2003). RN [7]; RE0023691. RX PUBMED: 11258482. RA Bouallaga I., Massicard S., Yaniv M., Thierry F. RT An enhanceosome containing the Jun B/Fra-2 heterodimer and the HMG-I(Y) architectural protein controls HPV 18 transcription. RL EMBO Rep. 1:422-427 (2000). RN [8]; RE0024052. RX PUBMED: 10657993. RA Foster L. C., Wiesel P., Huggins G. S., Panares R., Chin M. T., Pellacani A., Perrella M. A. RT Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1beta in vascular smooth muscle cells. RL FASEB J. 14:368-378 (2000). RN [9]; RE0024055. RX PUBMED: 9880529. RA Pellacani A., Chin M. T., Wiesel P., Ibanez M., Patel A., Yet S. F., Hsieh C. M., Paulauskis J. D., Reeves R., Lee M. E., Perrella M. A. RT Induction of high mobility group-I(Y) protein by endotoxin and interleukin-1beta in vascular smooth muscle cells. Role in activation of inducible nitric oxide synthase. RL J. Biol. Chem. 274:1525-1532 (1999). RN [10]; RE0047237. RX PUBMED: 7594592. RA Nagulapalli S., Pongubala J. M., Atchison M. L. RT Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3) RL J. Immunol. 155:4330-8 (1995). RN [11]; RE0053460. RX PUBMED: 16707431. RA Paonessa F., Foti D., Costa V., Chiefari E., Brunetti G., Leone F., Luciano F., Wu F., Lee A. S., Gulletta E., Fusco A., Brunetti A. RT Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer. RL Cancer Res. 66:5085-5093 (2006). RN [12]; RE0053589. RX PUBMED: 17510387. RA Cleynen I., Huysmans C., Sasazuki T., Shirasawa S., Van de Ven W., Peeters K. RT Transcriptional control of the human high mobility group A1 gene: basal and oncogenic Ras-regulated expression. RL Cancer Res. 67:4620-4629 (2007). XX //